Vismodegib

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoma, Basal Cell

Conditions

Carcinoma, Basal Cell

Trial Timeline

Sep 17, 2015 → Mar 31, 2019

NCT ID

NCT02674009

About Vismodegib

Vismodegib is a pre-clinical stage product being developed by Roche for Carcinoma, Basal Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT02674009. Target conditions include Carcinoma, Basal Cell.

What happened to similar drugs?

20 of 20 similar drugs in Carcinoma, Basal Cell were approved

Approved (20) Terminated (1) Active (0)

✅Enfortumab VedotinAstellas PharmaApproved

✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved

✅LenvatinibEisaiApproved

✅Epirubicin + lipiodolJohnson & JohnsonApproved

✅ApatinibTabletsJiangsu Hengrui MedicineApproved

✅Gefitinib + DocetaxelAstraZenecaApproved

✅Olaparib + BevacizumabAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02674009	Pre-clinical	Completed	Sep 17, 2015	Mar 31, 2019	Carcinoma, Basal Cell
NCT02371967	Pre-clinical	Completed	Apr 8, 2015	Aug 19, 2020	Basal Cell Carcinoma
NCT01944943	Phase 2	Terminated	Feb 1, 2013	Oct 1, 2014	Diffuse Large B-cell Lymphoma
NCT01367665	Phase 2	Completed	Jul 1, 2011	Jun 14, 2017	Basal Cell Carcinoma

Competing Products

20 competing products in Carcinoma, Basal Cell

See all competitors

Product	Company	Stage	Hype Score
CD40 agonist mitazalimab in combination with chemotherapy	Alligator Bioscience AB	Phase 1/2	26
AFM24 + SNK01	Affimed	Phase 1/2	14
NRC-2694-A + Paclitaxel	Natco Pharma	Phase 2	42
Sintilimab + Nab paclitaxel + Cisplatin	CSPC Pharmaceutical Group Limited	Phase 2	35
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	18
Pemetrexed + Carboplatin	Eli Lilly	Phase 3	40
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cells	Precigen	Phase 1	27
Cemiplimab + Cetuximab	Eli Lilly	Phase 2	42
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FU	Eli Lilly	Phase 2	35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
CT-01 + EVEROLIMUS	Captor Therapeutics	Phase 1	26
BB-401	Benitec Biopharma	Phase 2	25
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	29
Azenosertib	Zentalis Pharmaceuticals	Phase 2	25
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	37
ateganosine + Cadonilimab	MAIA Biotechnology	Phase 1	26
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	35
Cetuximab	Eli Lilly	Phase 1	29
Ramucirumab + Paclitaxel	Eli Lilly	Phase 2	35